Igene Biotechnology, Inc.
Символ: IGNE
PNK
0.000001
USDПазарна цена днес
-0.0109
Съотношение P/E
-0.0001
Коефициент PEG
0.11M
MRK Cap
- 0.00%
Доходност на DIV
Igene Biotechnology, Inc. (IGNE) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2009 | 2008 | 2007 | 2006 | 2003 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3.82 | 1.3 | 1.5 | 1 | |||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.net-receivables | 8.77 | 2.3 | 1 | 2.7 | |||||||||
balance-sheet.row.inventory | 0 | 0 | 2.4 | 8.1 | |||||||||
balance-sheet.row.other-current-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-current-assets | 12.67 | 3.7 | 5 | 11.8 | |||||||||
balance-sheet.row.property-plant-equipment-net | 3.2 | 0.9 | 0.8 | 0.7 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0.6 | 0.1 | 0.1 | 0.1 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0.6 | 0.1 | 0.1 | 0.1 | |||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 0.34 | 0.1 | 0.1 | 0.4 | |||||||||
balance-sheet.row.total-non-current-assets | 4.14 | 1.1 | 1.1 | 1.3 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 16.81 | 4.8 | 6.1 | 13.1 | |||||||||
balance-sheet.row.account-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.short-term-debt | 5.81 | 1.1 | 0 | 0 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 22.85 | 5.7 | 5.4 | 19.3 | |||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 1.92 | 0.5 | 0 | 0 | |||||||||
balance-sheet.row.total-non-current-liabilities | 23.82 | 5.9 | 5.9 | 19.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-liab | 31.55 | 7.5 | 8.7 | 27.5 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 62.57 | 15.6 | 15.2 | 1.1 | |||||||||
balance-sheet.row.retained-earnings | -215.38 | -52.9 | -52.7 | -48.7 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.21 | 0.1 | 0 | 0 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 137.87 | 34.5 | 34.9 | 33.3 | |||||||||
balance-sheet.row.total-stockholders-equity | -14.74 | -2.7 | -2.7 | -14.4 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 16.81 | 4.8 | 6.1 | 13.1 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | -14.74 | - | - | - | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 16.81 | - | - | - | |||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-debt | 28.66 | 6.8 | 5.4 | 19.3 | |||||||||
balance-sheet.row.net-debt | 24.84 | 5.5 | 3.9 | 18.3 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2009 | 2008 | 2007 | 2006 | 2003 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -2.37 | -0.1 | -4 | -1.9 | |||||||||
cash-flows.row.depreciation-and-amortization | 0.14 | 0.2 | 0.1 | 0 | |||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.change-in-working-capital | 1.69 | 2.1 | 7.3 | 1.7 | |||||||||
cash-flows.row.account-receivables | 0.03 | 1 | 1.7 | -3.7 | |||||||||
cash-flows.row.inventory | 0 | 2.4 | 5.7 | 1.8 | |||||||||
cash-flows.row.account-payables | 0 | 0 | -4.3 | 0 | |||||||||
cash-flows.row.other-working-capital | 1.54 | -1.3 | 0 | 3.5 | |||||||||
cash-flows.row.other-non-cash-items | -1.14 | -2.2 | -2.8 | 1.5 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -1.68 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0.02 | -0.2 | -0.2 | -0.3 | |||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -0.1 | |||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0.02 | -0.2 | -0.2 | -0.4 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -0.7 | |||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 0.8 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0 | 0.1 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.01 | 0.1 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -1.65 | -0.2 | 0.5 | 1 | |||||||||
cash-flows.row.cash-at-end-of-period | 3.82 | 1.3 | 1.5 | 1 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 5.47 | 1.5 | 1 | 0 | |||||||||
cash-flows.row.operating-cash-flow | -1.68 | -0.1 | 0.7 | 1.3 | |||||||||
cash-flows.row.capital-expenditure | 0.02 | -0.2 | -0.2 | -0.3 | |||||||||
cash-flows.row.free-cash-flow | -1.67 | -0.3 | 0.5 | 1 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2009 | 2008 | 2007 | 2006 | 2003 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 4 | 7.6 | 2.3 | |||||||||
income-statement-row.row.cost-of-revenue | -0.04 | 2.9 | 6.4 | 1.7 | |||||||||
income-statement-row.row.gross-profit | 0.04 | 1 | 1.2 | 0.6 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 2.04 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 0.41 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | 0.54 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.operating-expenses | 0.64 | 1 | 3.4 | 0.5 | |||||||||
income-statement-row.row.cost-and-expenses | 0.6 | 3.9 | 9.8 | 2.2 | |||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.interest-expense | 0.06 | 0.1 | 2 | 2.2 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | 0.54 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 0.02 | 1 | 0.2 | 0 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 0.02 | 1 | 0.2 | 0 | |||||||||
income-statement-row.row.interest-expense | 0.06 | 0.1 | 2 | 2.2 | |||||||||
income-statement-row.row.depreciation-and-amortization | 0.14 | 0.2 | 0.1 | 0 | |||||||||
income-statement-row.row.ebitda-caps | -0.48 | - | - | - | |||||||||
income-statement-row.row.operating-income | -2.33 | -1.1 | -2.2 | 0.2 | |||||||||
income-statement-row.row.income-before-tax | -1.43 | 0 | -2 | 0.3 | |||||||||
income-statement-row.row.income-tax-expense | 1.78 | 0.2 | 1.8 | 2 | |||||||||
income-statement-row.row.net-income | -2.37 | -0.1 | -4 | -1.9 |
Често задавани въпроси
Какво е Igene Biotechnology, Inc. (IGNE) общи активи?
Igene Biotechnology, Inc. (IGNE) общите активи са 4759763.000.
Какъв е годишният приход на предприятието?
Годишните приходи са N/A.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -0.000.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -0.000.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е -0.036.
Какъв е общият приход на предприятието?
Общият приход е -0.270.
Каква е Igene Biotechnology, Inc. (IGNE) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -140747.000.
Какъв е общият дълг на фирмата?
Общият дълг е 6796435.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 990930.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 269290.000.